Intera Atlas
Run match
Sites / Parexel
Is this you?

Request access for Parexel with your @parexel.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Parexel

Unclaimed profile

Large SMO/CRO · Raleigh, North Carolina · ~2 main US early-phase sites (Baltimore MD, Los Angeles CA); 4 global hospital-based early-phase units; 21,000+ employees worldwide sites

WebsiteLinkedInRank for protocol
Intera lens
ICP 7Lift (cardio sample) 0.18Recruit soph 0.43
Quality Scorecard (1–100)
Overall65Recruit28Ops82Sponsor80Ther73

Performance (observed)

Historical trials
349
Completed
297
Terminated/Withdrawn
20
Completion rate
94%
Active now
23
Phase 2
35
Phase 3
6
Realized enrollment
19,714
First study year
2004
Years active
22
Match confidence
high
Enrollment velocity (inf)
896

Therapeutic

Areas
Broad - Phase I-IV clinical development, early-phase to late-phase services, portfolio optimization, regulatory strategy, market access, patient-focused strategy; advanced therapeutics including novel modalities, precision medicine
Specialties
Endocrinology & Metabolism, Obesity, Diabetes, Cardiovascular, GLP-1 programs, General Medicine, Phase I-IV
Breadth (conditions)
204
Languages
Multiple (global operations)
States
MD, CA

Recruitment (web observed)

Trial Finder
Yes
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y; strong marketing and thought leadership content
Capability notes
Hospital-based units provide infrastructure for recruitment; 21,000+ employees enable multi-site coordination; participant-centric approach mentioned

Relationships

Sponsors
Astellas Pharma Global Development, Inc.; Astellas Pharma Europe B.V.; Novo Nordisk A/S; Eli Lilly and Company; Bristol-Myers Squibb; Bayer
CROs
Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site); Green Cross Corporation; International Partnership for Microbicides, Inc.; MacroGenics; Parexel
Partnerships
340+ Site Alliance sites, Panthera (UK) partnership, Medidata collaboration
Owner / parent
PE-backed: EQT & Goldman Sachs (2021, $8.5B); founded 1982
Funding
Public company (formerly private)
Acquisitions
Strategic partnerships (SCTbio collaboration)
Expansion
Y; global expansion, SCRS Eagle Award 2024
Recent hiring
Y; 24,000+ professionals with expansion

Capacity & people

Investigators
—
Coordinators
—
CEO
Peyton Howell (as of May 2026)
VP Clinical Ops
Deb Tatton (President, Global Clinical & Data Operations)
VP Site Ops
Unknown
VP Recruitment
Oliver Fuhrmann (EVP, Early Phase and Europe Head); Amy Kissam-Sands (President, Operational Excellence, Delivery and Innovation)
Emails
Unknown

Tech & DCT

CTMS
Y; integrated clinical development platforms
EHR
Unknown; integrated systems
eSource
Yes
eConsent
Yes
Builds tech
Parexel Biotech (in-house tech development)
Home visits
Y; home nursing and telehealth for DCTs
DCT / decentralized
Y; 150+ decentralized trials, home nursing, telehealth, DTP drug shipments
Tech stack
Parexel Biotech division, digital solutions, patient engagement focus, advanced trial coordination systems
Recruiting visible
Y

Notes

Strong Intera fit: Large enterprise CRO (21,000+ employees, $2-5B revenue) with PE backing (EQT/GS 2021). Multiple US early-phase sites (Baltimore, Los Angeles) with hospital-based infrastructure. CEO Peyton Howell brings growth focus from previous roles at AmerisourceBergen. Recent leadership transition shows growth orientation. Multiple concurrent recruiting studies capability across sites and therapeutic areas. Hospital-based units provide institutional recruitment infrastructure. Patient-focused strategy aligns with recruitment platform positioning. Not as strong as ICON (fewer dedicated US early-phase sites) but solid multi-site SMO with large scale, PE backing, and growth focus. Good fit for Intera's patient recruitment coordination value at enterprise scale.

Recommendation features (sample indication)

Ind fit 0.32Liftability 0.18Overall65

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.